The Covid Era Tech Promises To Reinvent Cancer Treatment
Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning ...
U.S. port strike expected to have limited impact on healthcare supply chain: HHS
The Department of Health and Human Services ((HSS)) rules out a significant disruption to the healthcare supply chain amid a ...
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Pharma Letter14 小时
Aktis Oncology closes $175 million financing
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized ...
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings ...
默沙东集团收购Curon Biopharmaceutical的新型抗体CN201
新泽西州拉威 - 全球医疗保健领导者默沙东集团（NYSE: MRK）已完成收购Curon Biopharmaceutical的新型双特异性抗体CN201，从而增强其管线中用于治疗B细胞恶性肿瘤和自身免疫性疾病的潜在药物。这笔交易涉及约7.5亿美元的预付款和相关费用，将反映在默沙东集团第三季度的非GAAP业绩中。